TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All patients diagnosed as stage 2 HAT according to the diagnostic protocols in use at the treatment center (generally, if presence of parasites in blood, lymph node fluid or CSF and an elevated white blood cell count in the CSF, but this can vary from center to center) will be included if a written Informed Consent is given by the patient or a legally acceptable representative if the patient is a minor or unable to communicate.~* Pregnancy and breastfeeding women: On a case by case basis according to the guidelines of the National HAT Control Programme or the NGO, the Investigator will decide to treat the patient or to defer the treatment. In case of inclusion, the mother-child pairs or the children of lactating mothers will be closely monitored during treatment and follow up.~* Children under 2 years of age: On a case by case basis, the Investigator will decide to treat an infant with NECT or an alternative treatment (preferably eflornithine). In case of inclusion, these infants will be closely monitored during treatment and follow up like all children less than 12 years of age.~Exclusion Criteria:~* Unable to take oral medication, and impossibility to use a nasogastric tube.~* Treatment failure after nifurtimox-eflornithine treatment.~* Any other condition or reason for which the Investigator (or the responsible treating staff member) judges that another or no HAT treatment is warranted.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adolescents aged 1 to 17 years at diagnostic~* Documented Ph+ ALL~* Eligibility for the current local prospective therapeutic study of childhood ALL~* Informed consent given by the parents or by legal guardian~Exclusion Criteria:~* Abnormal hepatic functions~* Abnormal renal functions~* Active systemic bacterial, fungal or viral infection

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Good risk Ph+ALL (Type: OTHER): For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
- Poor risk Ph+ALL (Type: OTHER): For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endothelin Blockade in Patients With Single Ventricle Physiology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 12 years of age~* Single ventricle congenital heart disease~* Require cardiac magnetic resonance imaging (MRI) for clinical purposes.~Exclusion Criteria:~* \< 12 years of age~* Pregnancy or women who may become pregnant (sexually active and unwilling to use birth control)~* Patients taking cyclosporin or glyburide~* Patients with baseline liver dysfunction (aspartate aminotransferase or alanine aminotransferase \> 3 times upper limit of normal)~* Contraindications to MRI (including pacemakers)~* Use of Bosentan within one month prior to enrollment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosentan (Type: EXPERIMENTAL): Bosentan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable angina~* Low-density lipoprotein (LDL) cholesterol 70-160 mg/dl~Exclusion Criteria:~* Renal failure~* Age\>80~* Simvastatin current treatment\>20mg~* Hepatic disease~* Inflammatory diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin 80 mg (Type: ACTIVE_COMPARATOR): Patients were treated with simvastatin 80 mg for 6 weeks
- Ezetimibe 10 mg / Simvastatin 20 mg (Type: ACTIVE_COMPARATOR): Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* If female, cannot be of reproductive potential~* Diagnosed with heterozygous familial hypercholesterolemia~* Have been treated with an appropriate and~stable dose of statin± other lipid-lowering medication(s) for at least 6 weeks~Exclusion Criteria:~* Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor~* Homozygous familial hypercholesterolemia~* Severe chronic heart failure~* Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib (Type: EXPERIMENTAL): Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo tablet, orally, once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sensory Augmentation Methods in Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Experience of a stroke 6 months prior to participation~* Gait speed of at least 0.2 m/s~* Ability to walk on a treadmill without a cane or walker~* Provision of informed consent~Exclusion Criteria:~* Evidence of cerebellar damage~* Resting blood pressure higher than 220/110 mm Hg~* History of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living~* Preexisting neurological disorders or dementia~* Legal blindness or severe visual impairment~* History of DVT or pulmonary embolism within 6 months~* Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions~* Orthopedic injuries or conditions (e.g. joint replacements) in the lower extremities with the potential to alter the gait pattern

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sensory augmentation (Type: EXPERIMENTAL): Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
- Random vibration (Type: ACTIVE_COMPARATOR): Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic melanoma: Either unresectable Stage III or any Stage IV~* ECOG of 0 or 1~* HLA-A\*0201 haplotype~* Baseline tumor biopsy MART1/Melan-A expression present (in \>10% of tumor cells)~* Patient provides consent for all required biopsies~* Adequate intravenous access for leukapheresis~* Absolute lymphocyte count \>500/ul at least once within 30 days of leukapheresis~* Life expectancy greater than 4 months in the opinion of the study clinician~* Negative pregnancy test~Exclusion Criteria:~* Administration of systemic corticosteroids within 28 days of planned leukapheresis~* Administration of cytotoxic chemotherapy or anti-tumor immunotherapy within 28 days of planned leukapheresis~* Administration of radiotherapy within 28 days of planned leukapheresis with the exception of subjects accrued to Cohort 3~* Active autoimmunity requiring systemic immunosuppressive therapy~* HIV infection~* Previous enrollment on this protocol and infusion of MART1/Melan-A CTL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Different dose of CTL
- Cohort 2 (Type: EXPERIMENTAL): Different dose of CTL
- Cohort 3 (Type: EXPERIMENTAL): Combination of CTL with GMCSF +/- radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects aged between 35 and 70 years, inclusive~* type 2 diabetes with duration \>6 months and \<10 years~* for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas~* HbA1c \>=7.0% and \<=10.0%~* if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start~* written informed consent~Exclusion Criteria:~* history or presence of cancer or any clinically relevant diseases~* chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial infarction within the previous 6 months~* recurrent hypoglycemia~* abnormal lab tests at screening (ALAT and/or ASAT \>=3 times ULN), creatinine \>1.6 mg/dL in males and \>1.4 mg/dL in females~* clinically relevant ECG findings at screening~* treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months~* treatment with any other OHA than metformin or metformin plus sulfonylureas during the previous 3 months~* any systemic or topical treatment with drugs known to influence glucose metabolism

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- insulin glargine + exenatide + metformin (Type: EXPERIMENTAL): None
- Insulin glargine + sitagliptin + metformin (Type: EXPERIMENTAL): None
- insulin glargine + metformin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 1 and 20 years~* Referral for EEG in sleep~* Children/young adults whose parents/caregivers were informed about the aims of the study and have signed the Informed consent form~Exclusion Criteria:~* Children that were unable to follow the study protocol were excluded during the study

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin peroral (Type: EXPERIMENTAL): 0,1mg/kg melatonin will be given in the form of a syrup to the participant before EEG and vital functions monitoring
- Dexmedetomidine intranasally (Type: EXPERIMENTAL): 3 mcg/kg of dexmedetomidine in the form of a nasal spray will be given to the participant before EEG and vital functions monitoring
- Dexmedetomidine sublingually (Type: EXPERIMENTAL): 3 mcg/kg of dexmedetomidine will be given to the participant sublingually before EEG and vital functions monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Computerized Vestibular Rehabilitation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* GROUP 1: Healthy volunteers: Static visual acuity of at least 20/30 at testing distance~* GROUP 2: Vestibular patients: Unilateral or bilateral vestibular hypofunction, No central vestibular disorder, Static Visual Acuity of at least 20/30 at testing distance~Exclusion Criteria:~* GROUP 1: Peripheral or central vestibular disorder~* GROUP 2: Central vestibular disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Normal Volunteers (Type: None): Testing motor learning
- Vestibular hypofunction (Type: None): Testing feasibility of rehabilitation game

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Waldenstrom's macroglobulinemia~* CD20 positive by bone marrow immunohistochemistry or flow cytometry~* Presence of monoclonal paraprotein~* IgM level at least 2 times upper limit of normal (ULN)~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0-2~Life expectancy:~* At least 6 months~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 25,000/mm\^3~Hepatic:~* Bilirubin less than 2.5 times ULN~* SGOT less than 2.5 times ULN~Renal:~* Creatinine less than 2.5 mg/dL~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 6 months after study~* No serious comorbid disease~* No uncontrolled bacterial, fungal, or viral infection~* No other active malignancy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior rituximab~* No prior nucleoside analogue therapy~Chemotherapy:~* At least 30 days since prior chemotherapy~Endocrine therapy:~* At least 30 days since prior steroid therapy~* No concurrent corticosteroids~Radiotherapy:~* At least 30 days since prior radiotherapy~Surgery:~* Not specified~Other:~* No more than 2 prior courses of therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast in Modulating Exacerbations of Asthma in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children aged 2-14 years inclusive~* Doctor-diagnosed asthma~* Needing a beta-agonist inhaler at least once weekly on average for symptom relief~* At least one day lost from school in the past year, or significantly limited activity, because of asthma~* A history of asthma exacerbations associated with apparent respiratory viral infections~* Parent or guardian who is willing to provide informed consent~* Willing to give assent~Exclusion Criteria:~* Non-English speaking~* Unable to understand purpose of study and give consent~* Concomitant respiratory or other major illness e.g. cystic fibrosis, cardiac disease~* Currently using montelukast or other leukotriene receptor antagonist~* Using regular oral corticosteroid~* An asthma exacerbation requiring medical intervention during August 2005

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2 (randomisation)~* Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs (OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase inhibitor). All antidiabetic treatments should have been ongoing for at least 12 weeks prior to Visit 2 (randomisation) and doses should have been stable in this period of time~* Glycosylated haemoglobin (HbA1c) 7.0-10.0% (both inclusive) by central laboratory analysis~* Body mass index (BMI) below or equal to 40 kg/m\^2~Exclusion Criteria:~* Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or thiazolidinediones (TZDs) both within the last 12 weeks prior to Visit 2 (randomisation)~* Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)~* Uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg~* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12 months) or hypoglycaemic unawareness as judged by the investigator~* Life-threatening disease (e.g. cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp Simple (Type: EXPERIMENTAL): None
- IDegAsp Step wise (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete